DK2274321T3 - Opiorphinpeptidderivater som potente inhibitorer af enkephalin-nedbrydende ectopeptidaser - Google Patents

Opiorphinpeptidderivater som potente inhibitorer af enkephalin-nedbrydende ectopeptidaser Download PDF

Info

Publication number
DK2274321T3
DK2274321T3 DK09730759.9T DK09730759T DK2274321T3 DK 2274321 T3 DK2274321 T3 DK 2274321T3 DK 09730759 T DK09730759 T DK 09730759T DK 2274321 T3 DK2274321 T3 DK 2274321T3
Authority
DK
Denmark
Prior art keywords
peptide
octanoyl
peptide derivative
qrfsr
cooh
Prior art date
Application number
DK09730759.9T
Other languages
English (en)
Inventor
Catherine Rougeot
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK2274321T3 publication Critical patent/DK2274321T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (16)

1. Peptidderivat med formel (I):
(I). hvori: - ζ er et hydrogen atom, tyrosin, en Y-[linker]-, en cystein eller en C-[linker]-, - AAi er Q eller pyroglutamat (Glp), - AA2 er R, - AAs er F eller F(X), - AA4 er S(O-Alkanoyl), - AAs er R, - C-[linker]- betyder Cys-[NH-(CH2)n-CO]-, hvor n er et heltal mellem 1 og 20, - Y-[linker]- betyder Tyr-[NH-(CH2)n-CO]-, hvor n' er et heltal mellem 1 og 20, - F(X) betyder et phenylalanin, hvis phenylgruppe er substitueret med en eller flere halogenatomer, - S(O-Alkanoyl) betyder en serin, hvis hydroxylgruppe er substitueret med en lineær eller forgrenet alkanoyl-gruppe med fra 1 til 20 carbonatomer, - en hvilken som helst aminosyre af peptidet uafhængigt kan være enten i L-konfigurationen eller D-konfigurationen; hvor peptidderivatet, hvis peptidderivatet omfatter en cystein, eventuelt er en dimer.
2. Peptidderivat ifølge krav 1, hvor ζ er et hydrogenatom, cystein eller en C-[I in ker],
3. Peptidderivat ifølge krav 1, hvor ζ er et hydrogenatom, tyrosin eller en Y-[I in ker],
4. Peptidderivat ifølge krav 1 eller 2, hvor: - ζ er et hydrogenatom, cystein eller en C-[linker]-, og - AAi er Q.
5. Peptidderivat ifølge et hvilket som helst af kravene 1 til 4, som er QRFS(O-Alkanoyl)R, C-[linker]-QRF-S(O-octanoyl)-R eller C-[NH-(CH2)6-CO]-
QRFS(O-Alkanoyl)R.
6. Peptidderivat ifølge et hvilket som helst af kravene 1 til 5, hvor S(O-Alkanoyl) er en serin, hvis hydroxylgruppe er substitueret med en lineær eller forgrenet octanoyl- eller dodecanoyl-gruppe.
7. Peptidderivat ifølge krav 1, som er QRF-S(O-octanoyl)-R; CQRF-S(O-octanoyl)-R; CQRF-S(O-dodecanoyl)-R; C-(-HN-(CH2)8-CO-)-QRF-S(O-octanoyl)-R; C-[dQ]-RF-S(O-octanoyl)-[dR]; [dC]-QRF-S(O-octanoyl)-[dR]; C-(-HN-(CH2)6-CO-)-QRF-S(O-octanoyl)-R; C(-HN-(CH2)i2-CO-)QRF-S(O-octanoyl)-R; hvor: - S(O-octanoyl) betyder en serin, hvis hydroxylgruppe er substitueret med en octanoylgruppe, - S(O-dodecanoyl) betyder en serin, hvis hydroxylgruppe er substitueret med en dodecanoylgruppe.
8. Peptidderivat ifølge et hvilket som helst af kravene 1 til 7, som har inhibito-risk styrke imod neutral endopeptidase NEP og/eller aminopeptidase AP-N.
9. Peptidderivat ifølge krav 3, som har inhibitorisk styrke imod human NEP.
10. Peptidderivat ifølge 4, som er en dobbelt inhibitor af neutral endopeptidase NEP og aminopeptidase AP-N inhibitor.
11. Sammensætning omfattende mindst et peptidderivat ifølge et hvilket som helst af kravene 1 til 10 og en farmaceutisk acceptabel bærer.
12. Peptidderivat ifølge et hvilket som helst af kravene 1 til 10, til anvendelse ved behandling af sygdomme eller lidelser, hvor der søges en modulering af aktiviteten af membran-metallo-ectopeptidase.
13. Peptidderivat til anvendelse ifølge krav 12, hvor membran-metallo-ec-topeptidasen er en membran-zink-metallopeptidase.
14. Peptidderivat til anvendelse ifølge krav 12 eller 13, hvor membran-metallo-ectopeptidasen er NEP og/eller AP-N.
15. Peptidderivat til anvendelse ifølge et hvilket som helst af kravene 12 til 14, til anvendelse ved behandling af en sygdom eller lidelse udvalgt fra gruppen bestående af smerter, depressive lidelser, nedsat social aktivitet forbundet med seksualitet og hæmmet seksualadfærd.
16. Antistof, som er rettet imod et peptidderivat ifølge et af kravene 1 til 7.
DK09730759.9T 2008-04-07 2009-04-07 Opiorphinpeptidderivater som potente inhibitorer af enkephalin-nedbrydende ectopeptidaser DK2274321T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4292208P 2008-04-07 2008-04-07
PCT/EP2009/054171 WO2009124948A1 (en) 2008-04-07 2009-04-07 Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopetidases

Publications (1)

Publication Number Publication Date
DK2274321T3 true DK2274321T3 (da) 2019-03-18

Family

ID=40956908

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09730759.9T DK2274321T3 (da) 2008-04-07 2009-04-07 Opiorphinpeptidderivater som potente inhibitorer af enkephalin-nedbrydende ectopeptidaser

Country Status (21)

Country Link
US (3) US8889827B2 (da)
EP (1) EP2274321B1 (da)
JP (2) JP5788788B2 (da)
KR (1) KR20110028433A (da)
CN (1) CN102083851A (da)
AU (1) AU2009235484B2 (da)
BR (1) BRPI0906905B1 (da)
CA (1) CA2720778C (da)
CY (1) CY1121966T1 (da)
DK (1) DK2274321T3 (da)
ES (1) ES2714374T3 (da)
HR (1) HRP20190335T1 (da)
HU (1) HUE042998T2 (da)
IL (1) IL208543A (da)
LT (1) LT2274321T (da)
MX (1) MX2010011055A (da)
PL (1) PL2274321T3 (da)
PT (1) PT2274321T (da)
RU (2) RU2542365C2 (da)
SI (1) SI2274321T1 (da)
WO (1) WO2009124948A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1577320T3 (da) 2004-03-19 2012-10-15 Pasteur Institut Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider
BRPI0906905B1 (pt) * 2008-04-07 2022-09-13 Institut Pasteur Derivados de peptídeo, composição e uso de um derivado de peptídeo
FR2931362B1 (fr) * 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2637600B1 (fr) 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
ATE291927T1 (de) 1999-06-23 2005-04-15 Pasteur Institut Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
EP1216707B1 (en) 2000-12-22 2005-02-09 Institut Pasteur Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide
RU2223113C1 (ru) * 2002-05-29 2004-02-10 Золотарев Юрий Александрович Пептид, обладающий регулирующей биологической активностью на белковый синтез в гепатоцитах
DK1577320T3 (da) 2004-03-19 2012-10-15 Pasteur Institut Peptider afledt fra humant BPLP-protein, polynukleotider kodende for nævnte peptider og antistoffer rettet mod nævnte peptider
WO2008009276A1 (de) * 2006-07-21 2008-01-24 Jenoptik Laser, Optik, Systeme Gmbh Lateral verstellbare fassung für optische elemente
WO2008096276A2 (en) 2007-02-02 2008-08-14 Greenpharma Peptide inhibitors of metallo- ectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses
WO2009090265A1 (en) * 2008-01-18 2009-07-23 Institut Pasteur Method for identifying bplp and opiorphin agonists or antagonists
BRPI0906905B1 (pt) * 2008-04-07 2022-09-13 Institut Pasteur Derivados de peptídeo, composição e uso de um derivado de peptídeo
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
CA2645452A1 (en) 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker

Also Published As

Publication number Publication date
RU2010145158A (ru) 2012-05-20
MX2010011055A (es) 2011-02-21
SI2274321T1 (sl) 2019-04-30
US8889827B2 (en) 2014-11-18
HRP20190335T1 (hr) 2019-05-03
JP2015110651A (ja) 2015-06-18
US9273094B2 (en) 2016-03-01
PT2274321T (pt) 2019-03-21
AU2009235484A1 (en) 2009-10-15
JP5788788B2 (ja) 2015-10-07
WO2009124948A1 (en) 2009-10-15
RU2014153924A (ru) 2016-07-20
US20150065683A1 (en) 2015-03-05
PL2274321T3 (pl) 2019-06-28
CA2720778C (en) 2017-10-17
AU2009235484B2 (en) 2013-11-07
EP2274321B1 (en) 2018-12-05
RU2542365C2 (ru) 2015-02-20
CN102083851A (zh) 2011-06-01
ES2714374T3 (es) 2019-05-28
US20090253639A1 (en) 2009-10-08
IL208543A0 (en) 2010-12-30
IL208543A (en) 2016-10-31
JP2011517940A (ja) 2011-06-23
US8642729B2 (en) 2014-02-04
EP2274321A1 (en) 2011-01-19
BRPI0906905B1 (pt) 2022-09-13
CY1121966T1 (el) 2020-10-14
KR20110028433A (ko) 2011-03-18
BRPI0906905A2 (pt) 2021-06-29
LT2274321T (lt) 2019-03-12
US20110124571A1 (en) 2011-05-26
CA2720778A1 (en) 2009-10-15
HUE042998T2 (hu) 2019-07-29

Similar Documents

Publication Publication Date Title
US9714951B2 (en) Pharmaceutical compositions containing peptides derived from human BPLP protein
Einsiedel et al. Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics
More et al. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs
US9273094B2 (en) Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
Fanelli et al. Synthesis and characterization in vitro and in vivo of (l)-(Trimethylsilyl) alanine containing neurotensin analogues
HUE026131T2 (en) Beta-arresin effector and preparations and methods for their use
Orlandi-Mattos et al. Enkephalin related peptides are released from jejunum wall by orally ingested bromelain
Dzimbova et al. Kyotorphin analogues containing unnatural amino acids: synthesis, analgesic activity and computer modeling of their interactions with μ-receptor
Olimpieri et al. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors
Li Enzyme-Instructed Self-Assembly (EISA) of Small Molecules Inhibits Cancer Cells